Advances in kidney disease and health最新文献

筛选
英文 中文
Optimization of Dietary and Behavioral Strategies for Kidney Stone Prevention. 优化饮食和行为策略预防肾结石。
IF 3.1
Advances in kidney disease and health Pub Date : 2026-11-02 DOI: 10.1053/j.akdh.2026.09.015
Melanie Betz
{"title":"Optimization of Dietary and Behavioral Strategies for Kidney Stone Prevention.","authors":"Melanie Betz","doi":"10.1053/j.akdh.2026.09.015","DOIUrl":"https://doi.org/10.1053/j.akdh.2026.09.015","url":null,"abstract":"<p><p>Nutrition is an essential component of kidney stone prevention for many people with kidney stones. Registered dietitian nutritionists are best suited to provide nutrition education via Medical Nutrition Therapy, the gold standard for nutrition education and counseling. Despite the agreement that nutrition education should be given to people with kidney stones, few urologists or nephrologists partner with registered dietitian nutritionists. Nutrition recommendations should be individualized rather than applied uniformly across patients. For effective and realistic change, nutrition recommendations should also be individualized to type of kidney stone and 24-h urine chemistries, as well as other health goals and food preferences. Nutrition recommendations for kidney stones may include reducing sodium, nondairy animal protein, or added sugar-or increasing fluid, calcium, fruits, vegetables, or whole-food plant proteins in place of nondairy animal protein. Low oxalate diets limit intake of most vegetables, many fruits, all whole grains and most beans, nuts, and seeds. Dietary patterns that promote these foods are consistently associated with a lower risk of kidney stones, as these foods provide many different kidney stone inhibitors. Strict low oxalate diets should not be recommended. Instead, the focus should be on reducing oxalate bioavailability, primarily via adequate calcium from food.</p>","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149327932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Artificial Intelligence in Nephrology Education. 人工智能在肾脏学教育中的作用。
IF 3.1
Advances in kidney disease and health Pub Date : 2026-07-07 DOI: 10.1053/j.akdh.2026.06.003
Jing Miao, Charat Thongprayoon, Wisit Cheungpasitporn
{"title":"The Role of Artificial Intelligence in Nephrology Education.","authors":"Jing Miao, Charat Thongprayoon, Wisit Cheungpasitporn","doi":"10.1053/j.akdh.2026.06.003","DOIUrl":"https://doi.org/10.1053/j.akdh.2026.06.003","url":null,"abstract":"<p><p>Artificial intelligence (AI) and large language models are increasingly reshaping nephrology education. This review advances a hierarchical framework for understanding AI in nephrology education. At the primary level, AI may represent a scalable educational infrastructure that helps address the mismatch between educational demand and delivery capacity. At the secondary level, 3 mechanisms enable this infrastructure: workflow integration, continuous adaptation, and scalability. At the tertiary level, downstream outcomes include enhanced clinical reasoning, curriculum acceleration, burden reduction, improved patient education, and equitable access. However, safe and effective implementation requires addressing limitations related to accuracy, hallucinations, bias, transparency, privacy, and alignment with evolving clinical guidelines. Emerging innovations, including adaptive tutors, digital twins, and AI-orchestrated curricula, highlight a rapidly evolving educational ecosystem. Overall, AI and large language models hold substantial promise to modernize nephrology education and patient engagement, provided they are integrated with rigorous governance, continuous expert oversight, and ethical safeguards.</p>","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148400109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Drugs on the Horizon for Hypertension 高血压新药即将问世。
IF 3.1
Advances in kidney disease and health Pub Date : 2026-07-01 Epub Date: 2026-07-02 DOI: 10.1053/j.akdh.2026.02.005
Geonte G. Jackson, James M. Luther, Matthew R. Alexander
{"title":"New Drugs on the Horizon for Hypertension","authors":"Geonte G. Jackson,&nbsp;James M. Luther,&nbsp;Matthew R. Alexander","doi":"10.1053/j.akdh.2026.02.005","DOIUrl":"10.1053/j.akdh.2026.02.005","url":null,"abstract":"<div><div>Despite the current therapeutic options including lifestyle modifications and pharmacotherapy, blood pressure remains inadequately controlled in the majority of hypertensive individuals. Several new medications have been recently Food and Drug Administration approved or are in phase 1 or 2 clinical trials for hypertension. This includes the nonselective endothelin receptor antagonist aprocitentan, which was Food and Drug Administration approved in 2024 for uncontrolled hypertension. Aldosterone synthase inhibitors including baxdrostat, lorundrostat, and vicadrostat are in phase 1 or 2 trials for hypertension or chronic kidney disease with evidence of significant blood pressure lowering. Finally, the novel small-interfering RNA-based zilebesiran targeting angiotensinogen represents a new class of antihypertensive medications with durable blood pressure–lowering dosing only every 3 or 6 months. Each of these medications has unique properties that can potentially contribute to improvement in blood pressure control for individual patients and at the population level. Development of these novel antihypertensives promises a welcome set of new options for the treatment of hypertension.</div></div><div>Despite the current therapeutic options including lifestyle modifications and pharmacotherapy, blood pressure remains inadequately controlled in the majority of hypertensive individuals. Several new medications have been recently Food and Drug Administration approved or are in phase 1 or 2 clinical trials for hypertension. This includes the nonselective endothelin receptor antagonist aprocitentan, which was Food and Drug Administration approved in 2024 for uncontrolled hypertension. Aldosterone synthase inhibitors including baxdrostat, lorundrostat, and vicadrostat are in phase 1 or 2 trials for hypertension or chronic kidney disease with evidence of significant blood pressure lowering. Finally, the novel small-interfering RNA-based zilebesiran targeting angiotensinogen represents a new class of antihypertensive medications with durable blood pressure–lowering dosing only every 3 or 6 months. Each of these medications has unique properties that can potentially contribute to improvement in blood pressure control for individual patients and at the population level. Development of these novel antihypertensives promises a welcome set of new options for the treatment of hypertension.</div>","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 4","pages":"Pages 327-335"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148378339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is There a Role for Renal Revascularization in Atherosclerotic Renal Artery Stenosis? 肾血运重建在动脉粥样硬化性肾动脉狭窄中有作用吗?
IF 3.1
Advances in kidney disease and health Pub Date : 2026-07-01 Epub Date: 2026-11-04 DOI: 10.1053/j.akdh.2026.09.001
Mario Funes Hernandez, Vivek Bhalla
{"title":"Is There a Role for Renal Revascularization in Atherosclerotic Renal Artery Stenosis?","authors":"Mario Funes Hernandez,&nbsp;Vivek Bhalla","doi":"10.1053/j.akdh.2026.09.001","DOIUrl":"10.1053/j.akdh.2026.09.001","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Atherosclerotic renal artery stenosis is a prevalent cause of secondary hypertension and ischemic nephropathy, particularly in older adults with generalized atherosclerosis. While randomized controlled trials have generally failed to show benefit from renal artery revascularization over optimal medical therapy in unselected populations, observational data highlight subgroups that may derive meaningful improvement. This review synthesizes evidence on patient selection, diagnostic strategies, and revascularization outcomes. High-risk clinical profiles—including recurrent flash pulmonary edema, rapidly progressive kidney dysfunction, global renal ischemia or resistant hypertension—consistently predict greater benefit, particularly with hemodynamically significant lesions. Functional assessments, including trans-lesional pressure gradients, may outperform anatomical severity alone in predicting blood pressure response. Kidney function improvement after revascularization is more likely in patients with rapidly declining kidney function and bilateral ≥70% stenosis or a solitary kidney. Cardiovascular benefit appears greatest in recurrent flash pulmonary edema or congestive heart failure, preserved kidney function, and low albuminuria. Patients with moderate stenosis, controlled blood pressure, and stable kidney function generally show no added benefit from revascularization. Integrating anatomical imaging, physiological measurements, and clinical risk factors may optimize patient selection. Future prospective trials should target high-risk phenotypes excluded from prior studies, with standardized endpoints including ambulatory blood pressure, objective medication adherence, and clinically meaningful kidney and cardiovascular outcomes.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Atherosclerotic renal artery stenosis is a prevalent cause of secondary hypertension and ischemic nephropathy, particularly in older adults with generalized atherosclerosis. While randomized controlled trials have generally failed to show benefit from renal artery revascularization over optimal medical therapy in unselected populations, observational data highlight subgroups that may derive meaningful improvement. This review synthesizes evidence on patient selection, diagnostic strategies, and revascularization outcomes. High-risk clinical profiles—including recurrent flash pulmonary edema, rapidly progressive kidney dysfunction, global renal ischemia or resistant hypertension—consistently predict greater benefit, particularly with hemodynamically significant lesions. Functional assessments, including trans-lesional pressure gradients, may outperform anatomical severity alone in predicting blood pressure response. Kidney function improvement after revascularization is more likely in patients with rapidly declining kidney function and bilateral ≥70% stenosis or a solitary kidney. Cardiovascular benefit appears greatest in recurrent flash pulmonary edema or congestive heart failure, preserved kidn","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 4","pages":"Pages 346-357"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149308727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypertension in Patients Receiving Maintenance Hemodialysis: Beyond Sodium and Dry Weight 接受维持性血液透析患者的高血压:钠和干重
IF 3.1
Advances in kidney disease and health Pub Date : 2026-07-01 Epub Date: 2026-11-04 DOI: 10.1053/j.akdh.2026.07.005
Caroline Najjar, Brendan McCormick, Mark Canney
{"title":"Hypertension in Patients Receiving Maintenance Hemodialysis: Beyond Sodium and Dry Weight","authors":"Caroline Najjar,&nbsp;Brendan McCormick,&nbsp;Mark Canney","doi":"10.1053/j.akdh.2026.07.005","DOIUrl":"10.1053/j.akdh.2026.07.005","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Hypertension is highly prevalent in patients receiving maintenance hemodialysis and is strongly associated with adverse cardiovascular outcomes. Optimal strategies for diagnosis and management of hypertension are uncertain. Peridialysis blood pressure (BP) measurements, although critical for safety monitoring, are increasingly recognized as being unreliable for diagnosing hypertension or guiding therapy. Current evidence supports the use of 44-h ambulatory BP monitoring as the preferred diagnostic method, with home BP monitoring as a practical alternative. Out-of-office measurements correlate more closely with cardiovascular outcomes, left ventricular hypertrophy, and mortality than peridialysis readings. Despite observational data suggesting a linear association between higher out-of-dialysis BP and adverse outcomes, randomized controlled trials establishing definitive BP targets in dialysis patients are lacking. Both extremes of BP may confer harm, and aggressive BP lowering increases the risk of intradialytic hypotension and vascular access complications. Management should prioritize the optimization of volume status by attainment of dry weight and sodium restriction. If BP remains high, pharmacotherapy is indicated. Beta-blockers are generally favored as first-line agents given their antihypertensive efficacy and potential cardiovascular benefits. Future research should focus on the role of emerging cardiovascular therapies, large-scale clinical trials to establish appropriate BP targets, and real-world implementation of out-of-office BP measurements.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Hypertension is highly prevalent in patients receiving maintenance hemodialysis and is strongly associated with adverse cardiovascular outcomes. Optimal strategies for diagnosis and management of hypertension are uncertain. Peridialysis blood pressure (BP) measurements, although critical for safety monitoring, are increasingly recognized as being unreliable for diagnosing hypertension or guiding therapy. Current evidence supports the use of 44-h ambulatory BP monitoring as the preferred diagnostic method, with home BP monitoring as a practical alternative. Out-of-office measurements correlate more closely with cardiovascular outcomes, left ventricular hypertrophy, and mortality than peridialysis readings. Despite observational data suggesting a linear association between higher out-of-dialysis BP and adverse outcomes, randomized controlled trials establishing definitive BP targets in dialysis patients are lacking. Both extremes of BP may confer harm, and aggressive BP lowering increases the risk of intradialytic hypotension and vascular access complications. Management should prioritize the optimization of volume status by attainment of dry weight and sodium restriction. If BP remains high, pharmacotherapy is indicated. Beta-blockers are generally favored as first-line agents given their antihypertensive efficacy and potential cardiovascular benefits. Future research sh","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 4","pages":"Pages 317-326"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149308833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Renal Denervation in Modern Hypertension Care: From Early Promise to Evidence-Based Clinical Integration 现代高血压护理中的肾去神经:从早期的承诺到循证临床整合
IF 3.1
Advances in kidney disease and health Pub Date : 2026-07-01 Epub Date: 2026-11-04 DOI: 10.1053/j.akdh.2026.09.002
Ahmed Aldajani, Michael Froeschl, Derek YF. So, Hassan Mir, Pascal Theriault-Lauzier
{"title":"Renal Denervation in Modern Hypertension Care: From Early Promise to Evidence-Based Clinical Integration","authors":"Ahmed Aldajani,&nbsp;Michael Froeschl,&nbsp;Derek YF. So,&nbsp;Hassan Mir,&nbsp;Pascal Theriault-Lauzier","doi":"10.1053/j.akdh.2026.09.002","DOIUrl":"10.1053/j.akdh.2026.09.002","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Hypertension remains the leading modifiable risk factor for cardiovascular morbidity and mortality. However, rates of global blood pressure (BP) control remain suboptimal, despite effective pharmacologic therapies and clear guideline targets. Persistent gaps in control are multifactorial, including poor adherence, complex treatment regimens, and health care system limitations. Renal denervation (RDN), a device-based therapy, is an emerging treatment which may overcome barriers for hypertension control. RDN targets renal sympathetic nerve activity, a key contributor to hypertension pathophysiology. Early studies of RDN, using catheter-based ablation techniques, suggested substantial BP reductions (∼10-30 mmHg reduction in office systolic BP). However, initial enthusiasm was tempered by neutral findings in sham-controlled trials. Recent advances in device technology, procedural optimization, technique, and patient selection have been central to improving reproducibility and redemonstrating efficacy (office and ambulatory BP) and safety of RDN in contemporary randomized studies. Current evidence supports RDN as an adjunctive therapy in carefully selected patients with resistant or uncontrolled primary hypertension, particularly in those with preserved renal function and evidence of sympathetic overactivity. As the field evolves, ongoing research focusing on precision phenotyping, noncatheter-based techniques, long-term clinical outcomes, and cost-effectiveness will be critical in defining the role of RDN within contemporary hypertension management strategies.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Hypertension remains the leading modifiable risk factor for cardiovascular morbidity and mortality. However, rates of global blood pressure (BP) control remain suboptimal, despite effective pharmacologic therapies and clear guideline targets. Persistent gaps in control are multifactorial, including poor adherence, complex treatment regimens, and health care system limitations. Renal denervation (RDN), a device-based therapy, is an emerging treatment which may overcome barriers for hypertension control. RDN targets renal sympathetic nerve activity, a key contributor to hypertension pathophysiology. Early studies of RDN, using catheter-based ablation techniques, suggested substantial BP reductions (∼10-30 mmHg reduction in office systolic BP). However, initial enthusiasm was tempered by neutral findings in sham-controlled trials. Recent advances in device technology, procedural optimization, technique, and patient selection have been central to improving reproducibility and redemonstrating efficacy (office and ambulatory BP) and safety of RDN in contemporary randomized studies. Current evidence supports RDN as an adjunctive therapy in carefully selected patients with resistant or uncontrolled primary hypertension, particularly in those with preserved renal function and evidence of sympathetic overactivity. As the field evolves, ongoing research focusing on precision phen","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 4","pages":"Pages 336-345"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149308839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Out-of-Office Blood Pressure Monitoring in the Pediatric Population: Current Evidence and Pitfalls 门诊外血压监测在儿科人群:目前的证据和缺陷
IF 3.1
Advances in kidney disease and health Pub Date : 2026-07-01 Epub Date: 2026-11-04 DOI: 10.1053/j.akdh.2026.08.003
Tammy M. Brady
{"title":"Out-of-Office Blood Pressure Monitoring in the Pediatric Population: Current Evidence and Pitfalls","authors":"Tammy M. Brady","doi":"10.1053/j.akdh.2026.08.003","DOIUrl":"10.1053/j.akdh.2026.08.003","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Out-of-office blood pressure (BP) measurement is essential for the accurate diagnosis and longitudinal management of hypertension in children and adolescents, yet evidence supporting modalities beyond ambulatory BP monitoring (ABPM) remains limited. This review synthesizes current pediatric evidence on out-of-office BP measurement approaches, including ABPM, home BP monitoring with cuff and cuffless devices, and community-based measurements, highlighting their advantages, limitations, and key evidence gaps. ABPM remains the only modality recommended for diagnostic confirmation in youth, owing to its superior reproducibility, ability to characterize BP phenotypes, and strong associations with target organ injury and future cardiovascular disease risk. However, access to ABPM is constrained by cost, limited availability of validated pediatric devices and cuff sizes, specialized expertise requirements, and patient tolerability concerns. Home BP monitoring and community-based measurements may enhance access and support ongoing management but place substantial responsibility on families and are not recommended for diagnosis. Across all modalities, the scarcity of BP devices validated for pediatric use represents a major barrier to equitable care. Future research should prioritize rigorous validation of pediatric BP devices, evaluation of feasibility and effectiveness of home and community-based strategies, and development of approaches that reduce burden on families while improving access to accurate BP assessment in youth.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Out-of-office blood pressure (BP) measurement is essential for the accurate diagnosis and longitudinal management of hypertension in children and adolescents, yet evidence supporting modalities beyond ambulatory BP monitoring (ABPM) remains limited. This review synthesizes current pediatric evidence on out-of-office BP measurement approaches, including ABPM, home BP monitoring with cuff and cuffless devices, and community-based measurements, highlighting their advantages, limitations, and key evidence gaps. ABPM remains the only modality recommended for diagnostic confirmation in youth, owing to its superior reproducibility, ability to characterize BP phenotypes, and strong associations with target organ injury and future cardiovascular disease risk. However, access to ABPM is constrained by cost, limited availability of validated pediatric devices and cuff sizes, specialized expertise requirements, and patient tolerability concerns. Home BP monitoring and community-based measurements may enhance access and support ongoing management but place substantial responsibility on families and are not recommended for diagnosis. Across all modalities, the scarcity of BP devices validated for pediatric use represents a major barrier to equitable care. Future research should prioritize rigorous validation of pediatric BP devices, evaluation of feasibility and effectiveness of home and community-based strategies, and ","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 4","pages":"Pages 282-293"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149308835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypertension Treatment, Race, and Diaspora 高血压治疗、种族和移民
IF 3.1
Advances in kidney disease and health Pub Date : 2026-07-01 Epub Date: 2026-11-04 DOI: 10.1053/j.akdh.2026.09.005
Holly J. Kramer
{"title":"Hypertension Treatment, Race, and Diaspora","authors":"Holly J. Kramer","doi":"10.1053/j.akdh.2026.09.005","DOIUrl":"10.1053/j.akdh.2026.09.005","url":null,"abstract":"","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 4","pages":"Pages 279-281"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149308837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypertension in Children With Chronic Kidney Disease and Dialysis: State of the Art 患有慢性肾病和透析的儿童高血压:最新进展
IF 3.1
Advances in kidney disease and health Pub Date : 2026-07-01 Epub Date: 2026-11-04 DOI: 10.1053/j.akdh.2026.08.007
Deirdre O’ Sullivan, Emily Haseler, Manish D. Sinha
{"title":"Hypertension in Children With Chronic Kidney Disease and Dialysis: State of the Art","authors":"Deirdre O’ Sullivan,&nbsp;Emily Haseler,&nbsp;Manish D. Sinha","doi":"10.1053/j.akdh.2026.08.007","DOIUrl":"10.1053/j.akdh.2026.08.007","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Hypertension is a highly prevalent and clinically significant complication in childhood chronic kidney disease (CKD), contributing substantially to cardiovascular morbidity, progression of kidney dysfunction, and long-term health risks extending into adulthood. Management of hypertension remains suboptimal with missed opportunities in its accurate detection, monitoring, and subsequent risk stratification to improve clinical outcomes. Evidence consistently demonstrates that sustained hypertension accelerates decline in glomerular filtration rate and increases the risk of left ventricular hypertrophy and other forms of target organ injury. Early and effective intervention, therefore, is essential. Nonpharmacological strategies, including dietary sodium restriction, optimization of fluid balance, and promotion of healthy lifestyle habits, form the foundation of management. Pharmacological therapy, particularly with agents that block the renin-angiotensin-aldosterone system, remains the cornerstone of treatment due to their dual antihypertensive and renoprotective effects. Randomized controlled trials have informed treatment thresholds and targets for those with predialysis CKD. Several knowledge gaps remain including blood pressure targets for earlier stages of CKD especially in those with non-proteinuric kidney disease, longer term safety data for antihypertensive medications, and studies highlighting successful implementation treatment strategies that improve achievement of tretament targets and outcomes require further investigation. Early recognition, routine use of ambulatory monitoring, and comprehensive, individualized management are essential to slow kidney disease progression and reduce cardiovascular risk, ultimately improving long-term outcomes for this vulnerable population.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Hypertension is a highly prevalent and clinically significant complication in childhood chronic kidney disease (CKD), contributing substantially to cardiovascular morbidity, progression of kidney dysfunction, and long-term health risks extending into adulthood. Management of hypertension remains suboptimal with missed opportunities in its accurate detection, monitoring, and subsequent risk stratification to improve clinical outcomes. Evidence consistently demonstrates that sustained hypertension accelerates decline in glomerular filtration rate and increases the risk of left ventricular hypertrophy and other forms of target organ injury. Early and effective intervention, therefore, is essential. Nonpharmacological strategies, including dietary sodium restriction, optimization of fluid balance, and promotion of healthy lifestyle habits, form the foundation of management. Pharmacological therapy, particularly with agents that block the renin-angiotensin-aldosterone system, remains the cornerstone of treatment due to their dual antihypertensive and renoprotective effects. Randomized controlled trials have informed treatment thresholds and targe","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 4","pages":"Pages 302-316"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149308802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preeclampsia and Risk of Future Hypertension in Women and Offspring 子痫前期与女性及后代未来高血压的风险
IF 3.1
Advances in kidney disease and health Pub Date : 2026-07-01 Epub Date: 2026-11-04 DOI: 10.1053/j.akdh.2026.09.013
Andrew F. Schiff, Silvi Shah, Andrew M. South
{"title":"Preeclampsia and Risk of Future Hypertension in Women and Offspring","authors":"Andrew F. Schiff,&nbsp;Silvi Shah,&nbsp;Andrew M. South","doi":"10.1053/j.akdh.2026.09.013","DOIUrl":"10.1053/j.akdh.2026.09.013","url":null,"abstract":"<div><div>Although a pregnancy-specific condition, preeclampsia is believed to be an indicator of higher future risk of cardiovascular morbidity and mortality in women and offspring over their life course. Factors such as diagnostic criteria and overlapping features with other hypertensive disorders of pregnancy have made it challenging to understand the precise pathophysiologic mechanisms that contribute to future cardiovascular disease for both women and offspring. Unique pathophysiological features of preeclampsia distinguish it from the other hypertensive disorders of pregnancy. Increasing preeclampsia prevalence and growing health care concerns regarding higher lifelong cardiovascular morbidity to mothers and offspring beyond pregnancy has prompted this comprehensive review consisting of (1) early-programming of hypertension and preeclampsia; (2) updated clinical and epidemiological evidence; (3) key health and population considerations; (4) clinical considerations specific to maternal-fetal medicine, neonatology, hypertension subspecialties, and primary care; and (5) key knowledge gaps to prioritize and future directions. Finally, we review the cardiovascular-kidney-metabolic framework as it relates to the hypertensive disorders of pregnancy.</div></div><div>Although a pregnancy-specific condition, preeclampsia is believed to be an indicator of higher future risk of cardiovascular morbidity and mortality in women and offspring over their life course. Factors such as diagnostic criteria and overlapping features with other hypertensive disorders of pregnancy have made it challenging to understand the precise pathophysiologic mechanisms that contribute to future cardiovascular disease for both women and offspring. Unique pathophysiological features of preeclampsia distinguish it from the other hypertensive disorders of pregnancy. Increasing preeclampsia prevalence and growing health care concerns regarding higher lifelong cardiovascular morbidity to mothers and offspring beyond pregnancy has prompted this comprehensive review consisting of (1) early-programming of hypertension and preeclampsia; (2) updated clinical and epidemiological evidence; (3) key health and population considerations; (4) clinical considerations specific to maternal-fetal medicine, neonatology, hypertension subspecialties, and primary care; and (5) key knowledge gaps to prioritize and future directions. Finally, we review the cardiovascular-kidney-metabolic framework as it relates to the hypertensive disorders of pregnancy.</div>","PeriodicalId":72096,"journal":{"name":"Advances in kidney disease and health","volume":"33 4","pages":"Pages 294-301"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149308836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书